Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

A new study from UCLA Health suggests COVID-19 vaccines may protect patients from severe kidney damage. The study found ...

England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Blue Cross Blue Shield of Michigan is engaged in the most consequential reimbursement negotiations with hospitals in its 86-year history. The Detroit insurer, the state’s most dominant with a 63% ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Women who use an oral contraceptive might want to consider using a back-up method after starting a weight loss drug.

A study from Mass General Brigham and Harvard Medical School raises questions about a new class of weight loss drugs — and ...